Signaturefd LLC Reduces Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Signaturefd LLC lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 33.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,571 shares of the biopharmaceutical company’s stock after selling 1,283 shares during the quarter. Signaturefd LLC’s holdings in Royalty Pharma were worth $66,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of RPRX. Swedbank AB grew its holdings in shares of Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after acquiring an additional 1,136,800 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Royalty Pharma by 58.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock worth $84,915,000 after purchasing an additional 1,103,341 shares during the period. Two Sigma Advisers LP raised its holdings in Royalty Pharma by 44.7% in the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after purchasing an additional 936,900 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Royalty Pharma during the fourth quarter valued at $19,990,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Royalty Pharma during the 3rd quarter valued at $14,898,000. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Price Performance

RPRX opened at $33.75 on Tuesday. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The stock has a 50-day moving average price of $32.33 and a 200-day moving average price of $28.75. The firm has a market cap of $19.46 billion, a PE ratio of 23.28, a P/E/G ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a $0.22 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.61%. Royalty Pharma’s dividend payout ratio (DPR) is presently 60.69%.

Analyst Ratings Changes

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Royalty Pharma has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.